Macrolides for treatment of chronic obstructive pulmonary disease

被引：0

作者：

Sun XueJiao ^{[1
,2
]}

He ZhiYi

机构：

[1] Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

[2] Department of Respiratory and Critical Care Medicine, Liuzhou General Hospital, Liuzhou, Guangxi, China

来源：

中华医学杂志英文版 | 2019年 / 132卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R563.9 [其他];

学科分类号：

1002 ; 100201 ;

摘要：

<正>

引用

页码：1261 / 1263

页数：3

共 18 条

[1]

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary[J] . Claus F. Vogelmeier,Gerard J. Criner,Fernando J. Martinez,Antonio Anzueto,Peter J. Barnes,Jean Bourbeau,Bartolome R. Celli,Rongchang Chen,Marc Decramer,Leonardo M. Fabbri,Peter Frith,David M.G. Halpin,M. Victorina Lo?pez Varela,Masaharu Nishimura,Nicolas Roche,Roberto Rodriguez-Roisin,Don D. Sin,Dave Singh,Robert Stockley,J?rgen Vestbo,Jadwiga A. Wedzicha,Alv

[2]

Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis[J] . Kuse Naoyuki,Abe Shinji,Hayashi Hiroki,Kamio Koichiro,Saito Yoshinobu,Usuki Jiro,Azuma Arata,Kudoh Shoji,Gemma Akihiko.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG . 2016 (3)

[3]

[Effects of mucolytic agents and macrolides in the treatment of COPD][J] . Yamaya Mutsuo.Nihon rinsho. Japanese journal of clinical medicine . 2016 (5)

[4]

Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly[J] . Stephanie Parks Taylor,Eric Sellers,Brice T. Taylor.The American Journal of Medicine . 2015 (12)

[5]

Non-anti-infective Effects of Antimicrobials and Their Clinical Applications: A Review[J] . Sadarangani,Sapna P,Estes,Lynn L,Steckelberg,James M.Mayo Clinic Proceedings . 2015 (1)

[6]

Long-term antibiotic therapy reduces exacerbation frequency in patients with COPD but it remains unclear which patients to target[J] . Allinson James P,Donaldson Gavin C.Evidence-based medicine . 2014 (3)

[7]

Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial[J] . Sevim Uzun,Remco S Djamin,Jan A J W Kluytmans,Paul G H Mulder,Nils E van’t Veer,Anton A M Ermens,Aline J Pelle,Henk C Hoogsteden,Joachim G J V Aerts,Menno M van der Eerden.The Lancet Respiratory Medicine . 2014 (5)

[8]

Persistence of Th17/Tc17 Cell Expression upon Smoking Cessation in Mice with Cigarette Smoke-Induced Emphysema[J] . Min-Chao Duan,Hai-Juan Tang,Xiao-Ning Zhong,Ying Huang,Enrico Maggi.Clinical and Developmental Immunology . 2013

[9] Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs [J].

Mosholder, Andrew D. ;

Mathew, Justin ;

Alexander, John J. ;

Smith, Harry ;

Nambiar, Sumathi .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (18) :1665-1668

[10]

Erythromycin Enhances CD4 + Foxp3 + Regulatory T-Cell Responses in a Rat Model of Smoke-Induced Lung Inflammation[J] . Jing Bai,Shi-Lin Qiu,Xiao-Ning Zhong,Qiu-Ping Huang,Zhi-Yi He,Jian-Quan Zhang,Guang-Nan Liu,Mei-Hua Li,Jing-Min Deng,Kazuhito Asano.Mediators of Inflammation . 2012

← 1 2 →